FDA issues Complete Response letters ordering Safety Labeling Changes under FDAAA for Aranesp, Epogen, and Procrit
This is a discussion on FDA issues Complete Response letters ordering Safety Labeling Changes under FDAAA for Aranesp, Epogen, and Procrit within the FDA News forum, part of the Industry News and Updates category; FDA issues Complete Response letters ordering Safety Labeling Changes under FDAAA for Aranesp, Epogen, and Procrit More......
|
|||||||
| Register | Help | Members List | Mark Forums Read |
07-30-2008, 06:45 PM
|
|||
|
|||
FDA issues Complete Response letters ordering Safety Labeling Changes under FDAAA for Aranesp, Epogen, and Procrit
FDA issues Complete Response letters ordering Safety Labeling Changes under FDAAA for Aranesp, Epogen, and Procrit
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Complete Steroid Avoidance Worsens Rather Than Improves Liver Transplant Outcome | industry_news | Other Clinical Pharmacy News | 0 | 07-14-2008 06:31 PM |
| FDA goes neutral with new response letters | industry_news | Biotechnology News | 0 | 07-10-2008 06:00 PM |
| FDA issues an Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Re | industry_news | FDA News | 0 | 06-07-2008 07:30 PM |
| Pfizer updates safety information in the labeling for Exubera | industry_news | FDA News | 0 | 04-10-2008 12:39 PM |
| FDA issues an Early Communication about an Ongoing Safety Review for Botox | industry_news | FDA News | 0 | 02-26-2008 03:30 PM |
© 2008 DrugManagementForum™ powered by |
 |